(Q36835839)

16 August 2017

1 reference

title

Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials (English)

1 reference

16 August 2017

1 reference

Mary Ellen Sweeney

1

1 reference

16 August 2017

Rebecca R Johnson

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

Expert Opinion on Drug Metabolism & Toxicology

16 August 2017

published in

1 reference

16 August 2017

volume

3

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

441-450

1 reference

Prediction of Coronary Heart Disease Using Risk Factor Categories

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetim

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Deficiency of Niemann-Pick C1 Like 1 prevents atherosclerosis in ApoE-/- mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

21 January 2018

Sitosterol xanthomatosis

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Characterization of a new circulating recombinant form comprising HIV-1 subtypes C and B in southern Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regressio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Elevation of CKP induced by ezetimibe in monotherapy: report on two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.3.3.441

21 January 2018

Identifiers

DOI

10.1517/17425255.3.3.441

1 reference

16 August 2017

1 reference